BCRX
BioCryst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.96
−1.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 940.6M | 874.8M | 450.7M | 331.4M | 270.8M |
| Cost of Revenue | 719.4M | 19.1M | 12.5M | 4.7M | 6.6M |
| Gross Profit | 221.2M | 855.8M | 438.2M | 326.8M | 264.2M |
| Operating Expenses | |||||
| R&D Expense | 197.8M | 166.1M | 174.6M | 216.6M | 253.3M |
| SG&A Expense | 337.3M | 348.6M | 266.1M | 213.9M | 159.4M |
| General & Admin Expense | 64.0M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (335.0K) | — | — | — | — |
| Total Operating Expenses | 534.7M | 514.8M | 440.8M | 430.5M | 412.7M |
| Cost and Expenses | 1.3B | 533.8M | 453.3M | 435.1M | 419.3M |
| Operating Income (EBIT) | (313.2M) | 341.0M | (2.5M) | (103.7M) | (148.4M) |
| Non-Operating | |||||
| Interest Income | 9.8M | 10.7M | 14.7M | 15.8M | 5.1M |
| Interest Expense | 75.3M | 78.9M | 98.5M | 108.2M | 99.1M |
| Net Interest Income | (65.5M) | (68.2M) | (83.8M) | (92.5M) | (94.0M) |
| Other Non-Op Income/Expense | (68.0M) | (73.6M) | (84.4M) | (122.5M) | (95.9M) |
| Non-Operating Income (excl Interest) | (4.2M) | (5.3M) | (14.1M) | 14.3M | (3.1M) |
| EBT (Pre-Tax Income) | (381.2M) | 267.4M | (87.0M) | (226.2M) | (244.4M) |
| Income Tax Expense | 3.5M | 3.5M | 1.9M | 310.0K | 2.7M |
| Bottom Line | |||||
| Net Income | (384.7M) | 263.9M | (88.9M) | (226.5M) | (247.1M) |
| Earnings from Cont. Ops | (384.7M) | 263.9M | (88.9M) | (226.5M) | (247.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (384.7M) | 263.9M | (88.9M) | (226.5M) | (247.1M) |
| Per Share | |||||
| Basic EPS | ($1.44) | $1.26 | ($0.43) | ($1.18) | ($1.33) |
| Diluted EPS | ($1.50) | $1.21 | ($0.43) | ($1.18) | ($1.33) |
| Revenue Per Share | $3.70 | $4.17 | $2.18 | $1.72 | $1.46 |
| Shares | |||||
| Basic Shares Outstanding | 254.5M | 209.9M | 206.7M | 192.2M | 185.9M |
| Diluted Shares Outstanding | 265.2M | 218.6M | 206.7M | 192.2M | 185.9M |
| Profitability Metrics | |||||
| EBITDA | (302.9M) | 347.7M | 12.8M | (116.3M) | (143.9M) |
| D&A | 6.0M | 1.4M | 1.2M | 1.7M | 1.4M |
| EBIT | (308.9M) | 346.3M | 11.6M | (118.0M) | (145.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026